Construction company Ebenbuild secures funding from the Entrepreneurship and Innovation (EIC) program.
Ebenbuild, a groundbreaking company developing AI-driven digital twins of lungs, has recently secured €2.3 million in funding from the European Innovation Council (EIC) Accelerator. This non-dilutive capital is a testament to the potential of Ebenbuild's technology and its vision to become the leading health information platform for respiratory diseases [1][2].
A Game-Changer in Respiratory Health
Ebenbuild's flagship product, Twinhale, is the first scalable simulation tool for patient-specific, physiologically accurate predictions of drug deposition in the lungs. This innovative technology has already been utilised in pilot studies with PARI Pharma and Pieris Pharmaceuticals [1].
In a validation study, Twinhale outperformed existing models, providing highly accurate predictions of local drug deposition. Design decisions that would not have been possible with in vivo or in vitro testing were made using Twinhale [1].
Market Potential and Target Audience
Ebenbuild is targeting the €15 billion in silico trials market, alongside applications in intensive care unit (ICU) decision support. The platform aims to improve respiratory health outcomes by enabling virtual modeling of an individual’s lung physiology to predict disease progression and treatment responses, thereby enhancing personalized medicine approaches [1].
The primary target groups for Ebenbuild's technology are clinical researchers and pharmaceutical companies conducting digital or in silico clinical trials, especially in respiratory diseases. Additionally, healthcare providers in ICU or respiratory care units who require decision support tools tailored to individual patient lung dynamics are potential users [1].
Potentially, patients with chronic respiratory diseases could also benefit from personalized treatment strategies informed by the digital twin model [1].
Future Plans in CDSS and Personalized Medicine
Ebenbuild plans to advance its digital twin technology to enhance Clinical Decision Support Systems (CDSS), integrating AI and patient-specific data to guide treatment choices in real time. By enabling more precise, individualized simulations of lung function, the platform supports personalized medicine initiatives, facilitating tailored therapies in respiratory care [1].
The company also aims to expand commercial applications beyond clinical trials, potentially in hospital and healthcare settings where real-time patient management is critical [1].
Support and Future Investments
Ebenbuild is supported by High-Tech Gründerfonds (HTGF), Bayern Kapital, and several angel investors. The EIC fund offers up to €10 million for future equity financing to Ebenbuild [1][2].
The funding received by Ebenbuild will be used to further develop and scale the company's digital twin platform technology, with the ultimate goal of revolutionising respiratory health care.
Dr. Kei Müller, CEO and co-founder of Ebenbuild, states that the company's vision is to become the leading health information platform for respiratory diseases [1]. With its innovative technology and ambitious plans, Ebenbuild is well on its way to achieving this vision.
References: [1] Ebenbuild. (2022). Press Release: Ebenbuild Secures €2.3 Million in EIC Funding for Lung Digital Twin Platform. Retrieved from https://www.ebenbuild.com/press-release-ebenbuild-secures-2-3-million-in-eic-funding-for-lung-digital-twin-platform
[2] European Commission. (2022). EIC Accelerator - Project Details. Retrieved from https://ec.europa.eu/info/business-economy-euro/growth-competitiveness-and-innovation/growth-strategy/horizon-2020/eic-accelerator/eic-accelerator-project-details_en
- Ebenbuild's Twinhale technology, aimed at improving respiratory health outcomes, outperformed existing models in a validation study and has already been used in pilot studies with pharma companies like PARI Pharma and Pieris Pharmaceuticals.
- Targeting the €15 billion in silico trials market, Ebenbuild's digital twin platform is designed to enable virtual modeling of lung physiology to predict disease progression and treatment responses, supporting personalized medicine.
- The funding received from the European Innovation Council Accelerator, in addition to support from High-Tech Gründerfonds, Bayern Kapital, and angel investors, will be used to further develop and scale Ebenbuild's digital twin platform, with the goal of revolutionizing respiratory healthcare.
- The company is working towards enhancing Clinical Decision Support Systems (CDSS) and integrating AI to guide treatment choices in real-time, ultimately aiming to become the leading health information platform for respiratory diseases.
%20program.){kind=link}